Delhi, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions:
- Global Cancer Antibody Drug Conjugates Market: 2020 – 2030
- Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
- Approved Cancer Antibody Drug Conjugates: 16 Drugs
- Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage & Price Analysis
- Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
- Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
- Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication
Download Report: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
Combining the strong cytotoxic effects of chemotherapy drugs with the specificity of monoclonal antibodies, antibody-drug conjugates (ADCs) have become an innovative class of medicines. In 2001, Brentuximab vedotin (Adcetris) became the first ADC to be approved, primarily for the treatment of lymphoma. This signaled the start of a new era in oncology, one in which drugs could be delivered directly to cancer cells through targeted therapy, minimizing harm to surrounding healthy tissue. Since then, the field has developed rapidly, resulting in the regulatory approval of 16 ADCs, the most recent being Elahere for multiple gynecological tumors in 2022.
With an estimated value around USD 10 Billion in 2023, witnessing 35% rise from the previous year, the global cancer ADC market has experienced substantial growth in recent years. The market had already surpassed US$ 7 Billion in the first half of 2024 alone, demonstrating the rapid rate of development and uptake of these drugs. Due to its ability to target specific antigens that are overexpressed on cancer cells, ADCs have predominantly been used in the treatment of solid tumors and hematological malignancies. This has improved efficacy while lowering systemic toxicity. In addition to improving patient outcomes, this specificity makes ADCs an attractive option in the crowded oncology market.
Even though the majority of ADCs have been developed and approved for therapeutic use, there is increasing interest in the potential applications of ADCs in diagnostics and theranostics, an integrated approach that combines therapeutic and diagnostic capabilities. Even if they are still primarily in the research and preclinical stages, these applications open opportunities for a potential future that could improve personalized treatment. Researchers hope to develop dual-function drugs that diagnose and treat cancer, potentially altering the way doctors approach cancer management, as well as imaging agents that can identify tumors more accurately by using the targeting capabilities of ADCs.
The global cancer ADC market is distinguished by a number of strategic alliances and partnerships meant to improve development capacities and market penetration. The exclusive licensing deal that Day One and MabCare Therapeutics have for the development and commercialization of MTX-13 in June 2024 is one such example. These partnerships enable companies to leverage one another’s expertise in technology, clinical knowledge, or market access, which speeds up the time it takes to create new ADCs. The competitive environment is further characterized by significant investments for ADC development. In July 2024, for example, Myricx Bio announced the completion of a successful funding round of US$ 120.42 Million, demonstrating investor confidence in ADCs' ability to offer revolutionary cancer therapeutics.
It is anticipated that the ADC market would supass US$ 13 Billion in 2024 and continue to expand after that. Antibody engineering, linker technology, and the identification of novel tumor-specific antigens are driving this expected expansion, which are anticipated to expand the applications of ADC applications to hard-to-treat cancers. ADCs are anticipated to grow in versatility and efficacy with further scientific research, not only in oncology but also in treating other diseases where therapeutic benefits of targeted administration of cytotoxic drugs may be realized.
In conclusion, antibody-drug conjugates, with a strong base of clinical approvals and a rapidly growing market, offer a substantial leap in cancer therapy. Their distinct mode of action minimizes side effects while providing hope for better outcomes in the treatment of cancer. ADC technology is always evolving, and this market is well-positioned for continued growth and innovation in the years to come thanks to smart partnerships, significant investment, and teamwork. The standards of care in oncology and other fields may be redefined by ADCs as research develops and new uses are investigated.
